Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Eli Lilly has announced that it will discontinue the phase 3 rheumatoid arthritis ( RA ) program for Tabalumab, an anti-BAFF ( B cell activating factor ) monoclonal antibody, due to lack of efficacy. ...


the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Cimzia ( Certo ...


Dipeptidyl peptidase-4 inhibitors ( DPP4i ), such as Linagliptin, Saxagliptin, and Sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus ( T2DM ). DPP4 is a transmembrane glycoprot ...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Eli Lilly and Incyte have announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of Baricitinib in patients with active rheumatoid arthritis. Ba ...


A team of researchers has analysed the association between alcohol intake and incidence of rheumatoid arthritis in women. The prospective study has used data from The Swedish Mammography Cohort, a ...


Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional tr ...


Pain management is a high priority for patients with rheumatoid arthritis. Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the managem ...


Pain management is a high priority for patients with rheumatoid arthritis. Muscle relaxants include drugs that reduce muscle spasm ( for example benzodiazepines such as Diazepam ( Valium ), Alprazolam ...


Pegloticase ( Krystexxa ) is a potential new treatment option for patients with chronic gout intolerant to other urate-lowering therapies.An analisys has been performed to investigate safety ( adverse ...


Patients suffering from two serious autoimmune disorders which cause muscular inflammation are at increased risk of developing cardiovascular disease, says a group of Montreal researchers. Christian A ...


Rheumatoid arthritis patients who failed to respond to initial treatment with Rituximab ( MabThera, Rituxan ) ( a chimeric monoclonal antibody against the protein CD20 ) can still be successfully re-t ...


To manage the painful and incapacitating symptoms of rheumatoid arthritis ( RA ), a chronic, inflammatory joint disease, the majority of patients rely on disease-modifying antirheumatic drugs ( DMARDs ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In particular, B cell depletion with the ...